Irritant

Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.

Retrieved on: 
Wednesday, September 7, 2022
Inflammation, Irritant, COVID-19, Pharmacokinetics, Autoimmune disease, Atopic dermatitis, Research, Dermatitis, Degenerative disease, Immune tolerance, Hyperkinesia, Disease, U.S. Securities and Exchange Commission, Risk, Incidence, Maintenance, Burling, Rash, LinkedIn, Skin, Homeostasis, Half-life, SEC, CD200, Allergen, Myelocyte, GLOBE, Nasdaq, FDA, Twitter, Knowledge, AD, Face, Dermatology, Clinical trial, Acquisition, Industry, Patient, Vaccine, Pharmaceutical industry, Risk management, Facebook

Ducentis lead asset is DS-234, a fusion protein that is a highly selective and potent agonist of the CD200 receptor (CD200R).

Key Points: 
  • Ducentis lead asset is DS-234, a fusion protein that is a highly selective and potent agonist of the CD200 receptor (CD200R).
  • Given the early-stage nature of the DS-234 program, the Ducentis acquisition is not expected to have a material impact on Arcutis financial plans.
  • Ducentis Biotherapeutics is a pre-clinical stage biotech company aiming to develop novel therapies for autoimmune disease patients with poor treatment options.
  • This press release contains "forward-looking" statements, including, among others, statements regarding Arcutis proposed acquisition of Ducentis, including the prospects for development of Ducentis programs.

Juntendo University research: Itchy business: Investigating a cure for eczema

Retrieved on: 
Wednesday, September 7, 2022
Inflammation, Irritant, Atopic dermatitis, Autophagy, Protein, Aryl hydrocarbon receptor, HBDS, Mouse, Interleukin, Francine Niyonsaba, Skin, Quality of life, Allergen, Cell, Journal, Scabs, Association, Dermatitis, Journal of Clinical Investigation, Immune system, Juntendo University, Allergy, Patient, Medical device, Vaccine

Now, a team of researchers from Juntendo University, led by Franois Niyonsaba, has revealed a candidate called human--defensin-3 (hBD-3) with potential in this regard.

Key Points: 
  • Now, a team of researchers from Juntendo University, led by Franois Niyonsaba, has revealed a candidate called human--defensin-3 (hBD-3) with potential in this regard.
  • One of the characteristics of AD is the disruption of the outermost layer of the skin: the epidermal barrier.
  • Inside the cells that line this barrier, a mechanism called autophagy is involved in their differentiation and antimicrobial activity.
  • Using the skin of human patients and mice with AD, the state of autophagy in affected cells was first analyzed.

Juntendo University research: Itchy business: Investigating a cure for eczema

Retrieved on: 
Wednesday, September 7, 2022
Inflammation, Irritant, Atopic dermatitis, Autophagy, Protein, Aryl hydrocarbon receptor, HBDS, Mouse, Interleukin, Francine Niyonsaba, Skin, Allergen, Cell, Journal, Scabs, Association, Dermatitis, Journal of Clinical Investigation, Immune system, Juntendo University, Allergy, Patient, Medical device, Vaccine

Now, a team of researchers from Juntendo University, led by Franois Niyonsaba, has revealed a candidate called human--defensin-3 (hBD-3) with potential in this regard.

Key Points: 
  • Now, a team of researchers from Juntendo University, led by Franois Niyonsaba, has revealed a candidate called human--defensin-3 (hBD-3) with potential in this regard.
  • One of the characteristics of AD is the disruption of the outermost layer of the skin: the epidermal barrier.
  • Inside the cells that line this barrier, a mechanism called autophagy is involved in their differentiation and antimicrobial activity.
  • Using the skin of human patients and mice with AD, the state of autophagy in affected cells was first analyzed.

Truesse Launches Their Line of All-Natural Vegan Skincare Products

Retrieved on: 
Wednesday, August 31, 2022
Elasticity, Irritant, Greasy, Frustration, Vitamin A, Solution, Blemish, Genetically modified organism, Vitamin, Anxiety, Skin, Beauty, Paraben, Mineral, AHA, Industry, Family, Cosmetics

DORAL, Fla., Aug. 31st, 2022 /PRNewswire/ -- Truesse is proud to announce the release of their groundbreaking line of skincare products.

Key Points: 
  • DORAL, Fla., Aug. 31st, 2022 /PRNewswire/ -- Truesse is proud to announce the release of their groundbreaking line of skincare products.
  • Born out of frustration with other skincare products and determination to do better, Truesse's new line of skincare products aims above the current standard of the industry.
  • As a result, Truesse's skincare products help customers feel confident about their skin and the products they use on it.
  • Truesse understands this struggle firsthand, which is why they created a new line of all-natural vegan skincare products that are designed to restore customers' skin and confidence at the same time.

Arcutis Completes Enrollment in INTEGUMENT-2 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

Retrieved on: 
Tuesday, August 23, 2022
Irritant, PDE4, Safety, IGA, Eczema Area and Severity Index, Atopic dermatitis, Dermatitis, Atopy, Time, Doctor of Philosophy, Disease, U.S. Securities and Exchange Commission, Risk, Itch, New Drug Application, FAAD, Week, Rash, Body surface area, LinkedIn, Skin, SEC, Success, Psoriasis, Allergen, Comparison (grammar), Validation, MD, GLOBE, Nasdaq, Company, FDA, COPD, Twitter, AD, Face, Shanda, Dermatology, Experimental cancer treatment, Patient, Health insurance, Pharmaceutical industry, Vaccine, Facebook

Roumilast cream is a once daily topical formulation of roumilast, a highly potent and selective phosphodiesterase type 4 inhibitor (PDE4).

Key Points: 
  • Roumilast cream is a once daily topical formulation of roumilast, a highly potent and selective phosphodiesterase type 4 inhibitor (PDE4).
  • The Company completed enrollment in an identically designed pivotal Phase 3 trial, INTEGUMENT-1, earlier in August 2022, with topline data from both trials expected by end of 2022.
  • Atopic dermatitis is the most common type of eczema, aecting approximately 9.6 million children and 16.5 million adults in the United States.
  • We are excited to have completed enrollment in the second of two phase 3 pivotal trials with roflumilast cream 0.15% in individuals with atopic dermatitis age six years and older, just weeks after closing enrollment for INTEGUMENT-1.

Lifestyle & Preparedness Expert Cheryl Nelson Offers Back-to-School Preparation Tips

Retrieved on: 
Monday, August 15, 2022
Primary, Secondary, Education, Lifestyle, Health, Consumer, Parenting, Vitamins, Supplements, Irritant, Vitamin, Industry, Mineral, Melatonin, Hammer, Family, Parent, Clothing, Vitamin C, Child, Arm, KSAT, Common, Immune system, Toy, Zinc

From establishing morning and nightly routines to school supply shopping and more, Cheryl Nelson, lifestyle and preparedness expert and founder of PrepareWithCher.com , offers her tips to help parents ensure their children are best equipped for their return to school.

Key Points: 
  • From establishing morning and nightly routines to school supply shopping and more, Cheryl Nelson, lifestyle and preparedness expert and founder of PrepareWithCher.com , offers her tips to help parents ensure their children are best equipped for their return to school.
  • Whether simply getting back into the swing of routines or starting at a new school, many families find this time of year challenging, says Nelson.
  • To help ease this stress, parents can implement simple lifestyle adjustments and preparation techniques to tackle the year as best as they can.
  • Nelson recommends the following tips to prepare for back-to-school:
    Start bedtime routines earlier.

Winston-Salem Weaver fire air quality worse than reported by agencies

Retrieved on: 
Thursday, August 4, 2022
Freedom of Information Act (United States), Irritant, Atmosphere, Asthma, Degenerative disease, Particulates, Prevalence, EPA, Wake Forest University, Freedom, Environmental quality, FOIA, North Carolina Department of Environmental Quality, Health, Environmental remediation

BREDL has recently received EPA air quality data through the Freedom of Information Act (FOIA) which show that hazardous air quality conditions were downplayed during this industrial incident.

Key Points: 
  • BREDL has recently received EPA air quality data through the Freedom of Information Act (FOIA) which show that hazardous air quality conditions were downplayed during this industrial incident.
  • The report compares official statements to the then current air quality data, specifically PM 2.5.
  • This air quality data was available to the fire command center in real time but was not available to the general public.
  • Barker said, "Our analysis leads us to make several recommendations for local, state and federal officials during industrial incidents: be transparent in reporting air quality and associated health impacts, make air quality data available to the public, include an air quality expert in incident press briefings and statements, utilize EJScreen to identify vulnerable communities, and incorporate temporary air monitors into existing EPA current air quality maps."

Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

Retrieved on: 
Thursday, August 4, 2022
Dermatitis, Comparison (grammar), Form 10-K, Inflammation, Atopic dermatitis, Skin, COPD, Allergen, Eczema Area and Severity Index, Success, Patient, U.S. Securities and Exchange Commission, Company, FAAD, Validation, Nasdaq, Safety, FDA, LinkedIn, Disease, IGA, Rash, Atopy, Psoriasis, Experimental cancer treatment, Irritant, Risk, Week, Time, Face, AD, PDE4, GLOBE, New Drug Application, Twitter, MD, Doctor of Philosophy, Dermatology, Body surface area, Shanda, SEC, Health insurance, Vaccine, Pharmaceutical industry, Medical imaging, Facebook, Pediatrics

Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 inhibitor (PDE4).

Key Points: 
  • Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 inhibitor (PDE4).
  • The Company is continuing enrollment in an identically designed pivotal Phase 3 trial, INTEGUMENT-2, with topline data from both trials expected by end of 2022.
  • We believe roflumilast cream, if approved, has the potential to be an effective and well-tolerated once-daily non-steroidal therapy for individuals with atopic dermatitis.
  • Arcutis is enrolling a third pivotal Phase 3 trial, the INterventional Trial EvaluatinG roflUMilast cream for the treatmENt of aTopic dermatitis in PEDiatric patients (INTEGUMENT-PED) to evaluate roflumilast cream 0.05% in children two to five years of age with mild to moderate AD.

NovaBay Pharmaceuticals Targets New Market with Antimicrobial Avenova® Lid and Lash Spray for Lash Extensions

Retrieved on: 
Thursday, July 28, 2022
Women, Specialty, Biotechnology, Pharmaceutical, Consumer, Health, Cosmetics, Optical, Retail, Online Retail, Register, NovaBay Pharmaceuticals, U.S. Securities and Exchange Commission, Irritant, Woman, Commercial, NYSE, VP, Private Securities Litigation Reform Act, Ophthalmology, Optometry, Security (finance), Life, Dust, Irritation, Form, Cosmetics

Years ago, we established Avenova spray as the premier antimicrobial lid and lash spray among optometrists and ophthalmologists.

Key Points: 
  • Years ago, we established Avenova spray as the premier antimicrobial lid and lash spray among optometrists and ophthalmologists.
  • Many women are turning to eyelash extensions to enhance their appearance while eliminating the need for mascara.
  • Avenova offers an ideal and differentiated solution to these bothersome issues for lash extensions users.
  • Avenova offers a viable solution to a very real unmet need for users of lash extensions with the added benefit of extending lash life.

LASKO LAUNCHES ALEXA-ENABLED TOWER FAN AND AIR PURIFIER

Retrieved on: 
Tuesday, July 19, 2022
Weather, Smoke, MSRP, Story, Human, Bacteria, Spore, Atmosphere of Earth, Safety, Engineering, Technology, Irritant, Volatile organic compound, Works, HEPA, Multimedia, Amazon (company), Allergen, Pollen, NAS Air King, Alexa, JACK Audio Connection Kit, LED, Humidifier, Dust, Laško, CADR, Mobile phone, Online shopping, Electronic component, Heating, ventilation, and air conditioning, Amazon, Guardian

WEST CHESTER, Pa., July 19, 2022 /PRNewswire/ -- Lasko Products, a market leader in home comfort, announced today the launch of two new Works with Alexa products – the Alexa-Enabled 48" Oscillating Tower Fan and Alexa-Enabled True HEPA Air Purifier – both exclusively available on Amazon.

Key Points: 
  • WEST CHESTER, Pa., July 19, 2022 /PRNewswire/ -- Lasko Products, a market leader in home comfort, announced today the launch of two new Works with Alexa products the Alexa-Enabled 48" Oscillating Tower Fan and Alexa-Enabled True HEPA Air Purifier both exclusively available on Amazon .
  • When a consumer owns an Alexa device and orders the Lasko 48" Oscillating Tower Fan or True HEPA Air Purifier through their Amazon account, the product can automatically pair with their Alexa speakers at home utilizing Alexa's Frustration-Free Setup technology.
  • Consumers can now control their Lasko fan or purifier with an Alexa device or use the Alexa app on any smart phone or tablet.
  • Operate all the fan and purifier functions with simple voice commands or set up routines that Alexa will perform automatically.